T S Kristedja - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Filters

T S Kristedja

Showing results (1-10 of 3) with videos related to

Pageof 1

Sort By:

Women'S Health (London, England)|October 5, 2010

Targeted agents in ovarian cancerT S Kristedja, R J Morgan, M Cristea

Cancer|August 16, 2001

High-dose tamoxifen added to concurrent biochemotherapy with decrescendo interleukin-2 in patients with metastatic melanomaS J O'Day, P D Boasberg, T S Kristedja, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999

Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanomaS J O'Day, G Gammon, P D Boasberg, et al.

Pageof 1

Search research articles

Showing results (1-10 of 3) with videos related to

Sort By:

Pageof 1

Women'S Health (London, England)|October 5, 2010

Targeted agents in ovarian cancerT S Kristedja, R J Morgan, M Cristea

Cancer|August 16, 2001

High-dose tamoxifen added to concurrent biochemotherapy with decrescendo interleukin-2 in patients with metastatic melanomaS J O'Day, P D Boasberg, T S Kristedja, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999

Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanomaS J O'Day, G Gammon, P D Boasberg, et al.

Pageof 1